First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13025
Abstract: The study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab (PemPBev) and paclitaxel/carboplatin/bevacizumab (PacCBev) as first‐line therapy for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC) patients with wild‐type driver genes in… read more here.
Keywords: bevacizumab; pemetrexed carboplatin; cisplatin bevacizumab; carboplatin ... See more keywords
24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9026
Abstract: 9026Background: Cohort G of the phase 1/2 KEYNOTE-021 study (NCT02039674) evaluated pembrolizumab (pembro) + pemetrexed and carboplatin (PC) vs PC in first-line advanced nonsquamous NSCLC. With med... read more here.
Keywords: first line; nonsquamous nsclc; cohort; pemetrexed carboplatin ... See more keywords
Real-world safety of pemetrexed, carboplatin, and pembrolizumab in U.S. NSCLC patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.5_suppl.50
Abstract: 50Background: A Phase 3 KEYNOTE-189 clinical trial showed improved clinical benefit with acceptable toxicity of pemetrexed combined with pembrolizumab and platinum (Gandhi, 2018). However, the safe... read more here.
Keywords: real world; carboplatin pembrolizumab; safety pemetrexed; pemetrexed carboplatin ... See more keywords